- Home
- Profiles


M. Cecilia Berin, PhD
- About Me
- Education & Certifications
- Research
- Publications
- Industry Relationships
About Me
Language
Position
Research Topics
Allergy, Antigen Presentation, Cellular Immunity, Chemokines, Cytokines, Dendritic Cells, Epithelial Cells, Immunology, Inflammation, Knockout Mice, Mucosal Immunology, T Cells
Multi-Disciplinary Training Areas
Immunology [IMM]
About Me
Language
Position
Research Topics
Allergy, Antigen Presentation, Cellular Immunity, Chemokines, Cytokines, Dendritic Cells, Epithelial Cells, Immunology, Inflammation, Knockout Mice, Mucosal Immunology, T Cells
Multi-Disciplinary Training Areas
Immunology [IMM]
About Me
Language
Position
Research Topics
Allergy, Antigen Presentation, Cellular Immunity, Chemokines, Cytokines, Dendritic Cells, Epithelial Cells, Immunology, Inflammation, Knockout Mice, Mucosal Immunology, T Cells
Multi-Disciplinary Training Areas
Immunology [IMM]
Education
BSc(Hons), Queen's University
MSc, Queen's University
PhD, McMaster University
Postdoctoral, University of California, San Diego
Research
Publications
Selected Publications
- JAK1 inhibition with abrocitinib decreases allergen-specific basophil and T-cell activation in pediatric peanut allergy. Nicole Ramsey, Wajiha Kazmi, Matthew Phelan, Daniel Lozano-Ojalvo, M. Cecilia Berin. Journal of Allergy and Clinical Immunology: Global
- Allergen recognition by specific effector Th2 cells enables IL-2-dependent activation of regulatory T-cell responses in humans. Daniel Lozano-Ojalvo, Scott R. Tyler, Carlos J. Aranda, Julie Wang, Scott Sicherer, Hugh A. Sampson, Robert A. Wood, A. Wesley Burks, Stacie M. Jones, Donald Y.M. Leung, Maria Curotto de Lafaille, M. Cecilia Berin. Allergy: European Journal of Allergy and Clinical Immunology
- Untargeted serum metabolomic analysis reveals a role for purinergic signaling in FPIES. Daniel Lozano-Ojalvo, Xin Chen, David Dunkin, Charuta Agashe, Mary Grace Baker, J. Andrew Bird, Elena Molina, Anna Nowak-Wegrzyn, M. Cecilia Berin. Journal of Allergy and Clinical Immunology
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Berin did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.